Cargando…

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events

BACKGROUND: Granulocyte colony-stimulating factors are effective at reducing the risk and duration of neutropenia. The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgrastim. METHODS: Embase was searched for trials exami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bond, T Christopher, Szabo, Erika, Gabriel, Susan, Klastersky, Jean, Tomey, Omar, Mueller, Udo, Schwartzberg, Lee, Tang, Boxiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094503/ https://www.ncbi.nlm.nih.gov/pubmed/28614980 http://dx.doi.org/10.1177/1078155217714859

Ejemplares similares

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
por: Scholz, Markus, et al.
Publicado: (2009)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Review on lipegfilgrastim
por: Gasparic, Maja, et al.
Publicado: (2015)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Filgrastim therapy in a child with neutropenia induced by linezolid
por: Hernández Segurado, Marta, et al.
Publicado: (2013)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
por: Cobb, Patrick Wayne, et al.
Publicado: (2020)

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
por: Zou, Linglong, et al.
Publicado: (2016)

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003)

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2015)

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
por: Hegg, Roberto, et al.
Publicado: (2016)

Dipyrone/filgrastim: Neutropenia, agranulocytosis and lack of efficacy: 3 case reports
Publicado: (2021)

Zarzio(®), biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
por: Nahon, Sophie, et al.
Publicado: (2015)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_octtk3j9ijro3hua2qajr1hvhf